AR040352A1 - Derivados de indolinfenilsulfonamida - Google Patents
Derivados de indolinfenilsulfonamidaInfo
- Publication number
- AR040352A1 AR040352A1 ARP030102373A ARP030102373A AR040352A1 AR 040352 A1 AR040352 A1 AR 040352A1 AR P030102373 A ARP030102373 A AR P030102373A AR P030102373 A ARP030102373 A AR P030102373A AR 040352 A1 AR040352 A1 AR 040352A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- represents hydrogen
- alkoxy
- amino
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- -1 phenoxy, benzyloxy Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052736 halogen Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se refiere a derivados sustituidos de indolinfenilsulfonamida, a procedimientos para su preparación así como a su uso en medicamentos, especialmente como potentes compuestos activadores de PPAR-d, para la profilaxis y/o el tratamiento de enfermedades cardiovasculares, especialmente de dislipidemias y enfermedades cardíacas coronarias. Reivindicación 1: Compuestos de fórmula general (1) en la que A representa el grupo C-R11 o N, en la que R11 representa hidrógeno o alquilo (C1-4), X representa O, S o CH2, R1 representa arilo (C6-10) o heteroarilo de 5 a 10 miembros con hasta tres heteroátomos del grupo de N, O y S, que pueden estar sustituidos a su vez respectivamente una a tres veces de forma igual o distinta con sustituyentes seleccionados del grupo de halógeno, ciano, nitro, alquilo (C1-6) que a su vez puede estar sustituido con hidroxi, alcoxi (C1-6), fenoxi, benciloxi, trifluormetilo, trifluormetoxi, alquelino (C2-6), fenilo, bencilo, alquil (C1-6)tio, alquil (C1-6)sulfonilo, alcanoilo (C1-6), alcoxi (C1-6)carbonilo, carboxilo, amino, acil (C1-6)amino, mono- y dialquil (C1-6)amino y heterociclilo de 5 a 6 miembros con hasta dos heteroátomos del grupo de N, O y/o S, o representa un grupo de la fórmula (2), R2 y R3 son iguales o distintos y representan independientemente entre sí hidrógeno o alquilo (C1-6) o, conjuntamente con el átomo de carbono al que están unidos, forman un anillo cicloalquilo con unión espiro de 3 a 7 miembros, R4 representa hidrógeno o alquilo (C1-6), R5 representa hidrógeno o alquilo (C1-6), R6 representa hidrógeno o alquilo (C1-6), R7 representa hidrógeno, alquilo (C1-6), alcoxi (C1-6) o halógeno, R8 y R9 son iguales o distintos y representan independientemente entre sí hidrógeno o alquilo (C1-4), y R10 representa hidrógeno o un grupo hidrolizable que puede degradarse al correspondiente ácido carboxílico, así como sus sales, solvatos y solvatos de las sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10229777A DE10229777A1 (de) | 2002-07-03 | 2002-07-03 | Indolin-Phenylsulfonamid-Derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040352A1 true AR040352A1 (es) | 2005-03-30 |
Family
ID=29796112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102373A AR040352A1 (es) | 2002-07-03 | 2003-06-30 | Derivados de indolinfenilsulfonamida |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20060100230A1 (es) |
| EP (1) | EP1519919A1 (es) |
| JP (1) | JP2005535649A (es) |
| CN (1) | CN1678581A (es) |
| AR (1) | AR040352A1 (es) |
| AU (1) | AU2003246638A1 (es) |
| BR (1) | BR0312549A (es) |
| CA (1) | CA2491477A1 (es) |
| DE (1) | DE10229777A1 (es) |
| EC (1) | ECSP055524A (es) |
| GT (1) | GT200300135A (es) |
| HN (1) | HN2003000196A (es) |
| HR (1) | HRP20050108A2 (es) |
| IL (1) | IL165924A0 (es) |
| MA (1) | MA27316A1 (es) |
| MX (1) | MXPA05000133A (es) |
| MY (1) | MY134641A (es) |
| NO (1) | NO20050579L (es) |
| NZ (1) | NZ537486A (es) |
| PE (1) | PE20040645A1 (es) |
| RU (1) | RU2328485C2 (es) |
| TW (1) | TW200418794A (es) |
| UA (1) | UA79003C2 (es) |
| UY (1) | UY27878A1 (es) |
| WO (1) | WO2004005253A1 (es) |
| ZA (1) | ZA200500013B (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10335450A1 (de) * | 2003-08-02 | 2005-02-17 | Bayer Ag | Indolin-Sulfanilsäureamide |
| DE10337839A1 (de) * | 2003-08-18 | 2005-03-17 | Bayer Healthcare Ag | Indolin-Derivate |
| JP2007504271A (ja) * | 2003-09-05 | 2007-03-01 | ニューロジェン・コーポレーション | Ｃｒｆ１受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類 |
| AR048523A1 (es) * | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
| EP1745003B1 (en) | 2004-05-05 | 2010-10-27 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| WO2005105736A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| FR2869904B1 (fr) | 2004-05-07 | 2006-07-28 | Fournier S A Sa Lab | Modulateurs des recepteurs lxr |
| FR2873694B1 (fr) * | 2004-07-27 | 2006-12-08 | Merck Sante Soc Par Actions Si | Nouveaux aza-indoles inhibiteurs de la mtp et apob |
| DK1805158T3 (en) * | 2004-10-29 | 2018-08-06 | Kalypsys Inc | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR |
| CN101421258B (zh) * | 2004-10-29 | 2013-08-21 | 凯利普西斯公司 | 作为ppar调节剂的磺酰基取代的双环化合物 |
| RU2007131501A (ru) * | 2005-01-18 | 2009-02-27 | Новартис АГ (CH) | Способы применения двойных агонистов ppar и устройств для доставки лекарственных средств, содержащих такие соединения |
| DE102005020230A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
| DE102005020229A1 (de) * | 2005-04-30 | 2006-11-09 | Bayer Healthcare Ag | Verwendung von Indolin-Phenylsulfonamid-Derivaten |
| FR2886293B1 (fr) * | 2005-05-30 | 2007-08-24 | Fournier S A Sa Lab | Nouveaux composes de l'indoline |
| ATE529404T1 (de) | 2005-06-30 | 2011-11-15 | High Point Pharmaceuticals Llc | Phenoxyessigsäuren als ppar-delta-aktivatoren |
| FR2890072A1 (fr) * | 2005-09-01 | 2007-03-02 | Fournier S A Sa Lab | Nouveaux composesde pyrrolopyridine |
| CN103224477A (zh) | 2005-12-22 | 2013-07-31 | 高点制药有限责任公司 | 作为PPAR-δ活化剂的苯氧基乙酸 |
| EP1999098A2 (en) | 2006-03-09 | 2008-12-10 | High Point Pharmaceuticals, LLC | Compounds that modulate ppar activity, their preparation and use |
| TWI315304B (en) | 2006-08-31 | 2009-10-01 | Univ Taipei Medical | Indoline-sulfonamides compounds |
| EP1932843A1 (en) * | 2006-12-14 | 2008-06-18 | sanofi-aventis | Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| TW200848021A (en) | 2007-03-06 | 2008-12-16 | Wyeth Corp | Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| BRPI0914978A2 (pt) * | 2008-06-09 | 2015-10-27 | Sanofi Aventis | sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos |
| WO2010000353A1 (en) * | 2008-06-09 | 2010-01-07 | Sanofi-Aventis | Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US20130196990A1 (en) | 2010-10-06 | 2013-08-01 | Junya Qu | Benzimidazole Derivatives As PI3 Kinase Inhibitors |
| EP2638014B1 (en) | 2010-11-08 | 2017-01-04 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ror-gamma activity and the treatment of diseases |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| RU2014149136A (ru) * | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
| JP6242868B2 (ja) * | 2012-05-08 | 2017-12-06 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用のためおよび疾患の処置のためのテトラヒドロ［１，８］ナフチリジンスルホンアミドおよび関連化合物 |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| EP3027616B1 (en) * | 2013-07-30 | 2018-01-10 | Boehringer Ingelheim International GmbH | Azaindole compounds as modulators of rorc |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN103626767A (zh) * | 2013-12-04 | 2014-03-12 | 上海药明康德新药开发有限公司 | 区域选择性的氮杂吲哚及其合成方法 |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
| CA2975997A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as rorgammat inhibitors and uses thereof |
| US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| WO2016201225A1 (en) | 2015-06-11 | 2016-12-15 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| US10287272B2 (en) | 2015-10-27 | 2019-05-14 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
| EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CN110483509B (zh) * | 2019-09-04 | 2020-08-25 | 温州大学 | 一种合成含氮杂环衍生物的方法 |
| CN110627785B (zh) * | 2019-09-19 | 2021-06-25 | 温州大学 | 一种1,5-四氢萘啶衍生物的制备方法 |
| JP7712932B2 (ja) * | 2019-12-18 | 2025-07-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｌｉｎ２８の阻害剤及びその使用方法 |
| KR20230050369A (ko) * | 2020-08-07 | 2023-04-14 | 카스마 테라퓨틱스, 인코포레이티드 | Trpml 조절제 |
| CN114702448A (zh) * | 2021-09-30 | 2022-07-05 | 西南大学 | 环烯烃的三氟甲基化串联环化螺环化合物的合成方法 |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2708605A1 (fr) * | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5795890A (en) * | 1995-09-27 | 1998-08-18 | Ono Pharmaceutical Co., Ltd. | Sulfonamide derivatives |
| FR2757157B1 (fr) * | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| AU2001277723A1 (en) * | 2000-08-11 | 2002-02-25 | Nippon Chemiphar Co., Ltd. | Ppardelta activators |
-
2002
- 2002-07-03 DE DE10229777A patent/DE10229777A1/de not_active Withdrawn
-
2003
- 2003-06-30 UA UAA200500952A patent/UA79003C2/uk unknown
- 2003-06-30 RU RU2005102592/04A patent/RU2328485C2/ru not_active IP Right Cessation
- 2003-06-30 MX MXPA05000133A patent/MXPA05000133A/es unknown
- 2003-06-30 HR HR20050108A patent/HRP20050108A2/hr not_active Application Discontinuation
- 2003-06-30 AU AU2003246638A patent/AU2003246638A1/en not_active Abandoned
- 2003-06-30 BR BR0312549-1A patent/BR0312549A/pt not_active IP Right Cessation
- 2003-06-30 CA CA002491477A patent/CA2491477A1/en not_active Abandoned
- 2003-06-30 CN CNA038209446A patent/CN1678581A/zh active Pending
- 2003-06-30 WO PCT/EP2003/006896 patent/WO2004005253A1/de not_active Ceased
- 2003-06-30 NZ NZ537486A patent/NZ537486A/en unknown
- 2003-06-30 JP JP2004518622A patent/JP2005535649A/ja not_active Withdrawn
- 2003-06-30 AR ARP030102373A patent/AR040352A1/es not_active Application Discontinuation
- 2003-06-30 US US10/519,125 patent/US20060100230A1/en not_active Abandoned
- 2003-06-30 EP EP03762547A patent/EP1519919A1/de not_active Withdrawn
- 2003-07-01 MY MYPI20032474A patent/MY134641A/en unknown
- 2003-07-02 UY UY27878A patent/UY27878A1/es not_active Application Discontinuation
- 2003-07-02 PE PE2003000668A patent/PE20040645A1/es not_active Application Discontinuation
- 2003-07-02 HN HN2003000196A patent/HN2003000196A/es unknown
- 2003-07-02 GT GT200300135A patent/GT200300135A/es unknown
- 2003-07-02 TW TW092118027A patent/TW200418794A/zh unknown
-
2004
- 2004-12-22 IL IL16592404A patent/IL165924A0/xx unknown
-
2005
- 2005-01-03 EC EC2005005524A patent/ECSP055524A/es unknown
- 2005-01-03 MA MA28032A patent/MA27316A1/fr unknown
- 2005-01-03 ZA ZA200500013A patent/ZA200500013B/en unknown
- 2005-02-02 NO NO20050579A patent/NO20050579L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0312549A (pt) | 2005-04-26 |
| ZA200500013B (en) | 2006-03-29 |
| CN1678581A (zh) | 2005-10-05 |
| MA27316A1 (fr) | 2005-05-02 |
| NO20050579L (no) | 2005-02-02 |
| HN2003000196A (es) | 2004-11-22 |
| UA79003C2 (en) | 2007-05-10 |
| TW200418794A (en) | 2004-10-01 |
| DE10229777A1 (de) | 2004-01-29 |
| PE20040645A1 (es) | 2004-10-29 |
| RU2328485C2 (ru) | 2008-07-10 |
| JP2005535649A (ja) | 2005-11-24 |
| GT200300135A (es) | 2004-03-17 |
| IL165924A0 (en) | 2006-01-15 |
| RU2005102592A (ru) | 2005-07-10 |
| MY134641A (en) | 2007-12-31 |
| MXPA05000133A (es) | 2005-04-11 |
| WO2004005253A1 (de) | 2004-01-15 |
| ECSP055524A (es) | 2005-03-10 |
| AU2003246638A1 (en) | 2004-01-23 |
| CA2491477A1 (en) | 2004-01-15 |
| HRP20050108A2 (hr) | 2006-04-30 |
| NZ537486A (en) | 2006-07-28 |
| UY27878A1 (es) | 2004-02-27 |
| EP1519919A1 (de) | 2005-04-06 |
| US20060100230A1 (en) | 2006-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040352A1 (es) | Derivados de indolinfenilsulfonamida | |
| AR045113A1 (es) | Derivados sustituidos del dioxido de tiazolbenzoisotiazol, procedimiento para su preparacion y su uso | |
| JP2016522172A5 (es) | ||
| AR051485A1 (es) | Pirazolo pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| AR034261A1 (es) | Compuestos derivados de pirazol[1,5-a]piridina; composiciones farmaceuticas, su uso en la fabricacion de medicamentos, y metodos de tratamiento de enfermedades mediadas por quinasas | |
| AR055606A1 (es) | Derivados de benzoquinazolina | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR034475A1 (es) | Derivados de androstano antiinflamatorios | |
| AR038686A1 (es) | Formulaciones de derivados de androstano y agonistas del adrenoreceptor beta 2 antiinflamatorios | |
| AR073406A1 (es) | Aminodihidrotiazinas fusionadas con tetrahidropiranos,inhibidoras de bace1 y de la produccion de abeta amiloide, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de enfermedades neurodegenerativas,tales como alzheimer. | |
| AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
| AR042525A1 (es) | Derivados de pirrolo-pirazoles sustituidos como inhibidores de quinasa | |
| AR045901A1 (es) | Glucocorticoesteroides especificos con actividades antiinflamatoria y antialergica,composiciones farmaceuticas que los contienen,y procedimientos para su preparacion, | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR072227A1 (es) | Derivados de triazinona sustituidos | |
| AR053082A1 (es) | DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS. | |
| AR039385A1 (es) | Derivados de tioxantina como inhibidores de la mieloperoxidasa | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| AR043658A1 (es) | Derivados 8-substituidos-6,7,8,9-tetrahidropirimido[1,2-a]pirimidin-4-ona | |
| AR058885A1 (es) | Compuestos de piperidina 3,5-sustituidos | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR037507A1 (es) | Derivados de acido acetico sustituidos, un procedimiento para su preparacion, medicamentos, un procedimiento para su preparacion, el uso de dichos compuestos para la preparacion de medicamentos | |
| AR063577A1 (es) | Derivados 8- piperidinil - pirimido [1 2 a] pirimidin -6-ona y 8- piperidinil-2- pirimidinil- pirimido [1,2-a] pirimidin -6- ona sustituidos | |
| RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| AR054991A1 (es) | Pteridinas sustituidas y su uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |